All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic artificial heart implantation

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F22%3A00083436" target="_blank" >RIV/00023001:_____/22:00083436 - isvavai.cz</a>

  • Result on the web

    <a href="https://reader.elsevier.com/reader/sd/pii/S1053249822019568?token=4B62134E6FABC4AE7CF7E7185B6B3A1E6BEA268D980B19E25EFCDA740DFCB424B71A2C203AA9ECBE254844D9519C1FC7&originRegion=eu-west-1&originCreation=20221206151435" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S1053249822019568?token=4B62134E6FABC4AE7CF7E7185B6B3A1E6BEA268D980B19E25EFCDA740DFCB424B71A2C203AA9ECBE254844D9519C1FC7&originRegion=eu-west-1&originCreation=20221206151435</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.healun.2022.05.017" target="_blank" >10.1016/j.healun.2022.05.017</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic artificial heart implantation

  • Original language description

    Antithrombotic therapy is mandatory in standard mechanical circulatory support, usually a vitamin K antagonist and/or antiplatelet agent is used. The autoregulated Aeson total artificial heart (A-TAH, Carmat SA, Vélizy-Villacoublay, France) is designed to replace the heart in patients with end-stage heart failure. For the European pivotal study, heparin and/or LMWH was proposed with a low antiXa target starting during the first post implant days. Fifteen (n = 15) male patients were implanted between September 2016 and December 2020. Intermediate dose LMWH anticoagulation was finally used in 12 patients with a median introduction time of 29.5 (range 8-152) days after A-TAH implantation. The results suggest that an intermediate-dose prophylactic anticoagulation with LMWH is feasible with no evidence of an increase in thrombotic complications or coagulation activation in patients implanted with the autoregulated A-TAH.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30201 - Cardiac and Cardiovascular systems

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2022

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Journal of heart and lung transplantation

  • ISSN

    1053-2498

  • e-ISSN

    1557-3117

  • Volume of the periodical

    41

  • Issue of the periodical within the volume

    9

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    4

  • Pages from-to

    1214-1217

  • UT code for WoS article

    000890162000007

  • EID of the result in the Scopus database

    2-s2.0-85132800172